| Literature DB >> 19193388 |
Robert A Dubie1, Saipiroon Maksaereekul, Barbara L Shacklett, Donna Lemongello, Kelly S Cole, Francois Villinger, Shelley A Blozis, Paul A Luciw, Ellen E Sparger.
Abstract
Simian immunodeficiency virus (SIV) infection of rhesus macaques is a valuable animal model for human immunodeficiency virus (HIV)-1 vaccine development. Our laboratory recently described the immunogenicity and limited efficacy of a vif-deleted SIVmac239 proviral DNA (SIV/CMVDelta vif) vaccine. The current report characterizes immunogenicity and efficacy for the SIV/CMVDelta vif proviral DNA vaccine when co-inoculated with an optimized rhesus interleukin (rIL)-15 expression plasmid. Macaques co-inoculated with rIL-15 and SIV/CMVDelta vif proviral plasmids showed significantly improved SIV-specific CD8 T cell immunity characterized by increased IFN-gamma ELISPOT and polyfunctional CD8 T cell responses. Furthermore, these animals demonstrated a sustained suppression of plasma virus loads after multiple low dose vaginal challenges with pathogenic SIVmac251. Importantly, SIV-specific cellular responses were greater in immunized animals compared to unvaccinated controls during the initial 12 weeks after challenge. Taken together, these findings support the use of IL-15 as an adjuvant in prophylactic anti-HIV vaccine strategies.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19193388 PMCID: PMC3640844 DOI: 10.1016/j.virol.2009.01.007
Source DB: PubMed Journal: Virology ISSN: 0042-6822 Impact factor: 3.616